Rex American Resources vs Westlake Chemical Partners LP
REX and WLKP side by side, both in chemicals and allied products. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How REX and WLKP compare
Rex American Resources is the larger company, worth 1.7 times as much as Westlake Chemical Partners LP ($1.3B against $747M).
Westlake Chemical Partners LP grew revenue faster over the last twelve months (9.4% versus 1.3% for Rex American Resources).
Westlake Chemical Partners LP pays a dividend yielding 6.7%; Rex American Resources does not pay one.
Westlake Chemical Partners LP scores higher on the StockData Score (13 against 12 for Rex American Resources), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | REX | WLKP |
|---|---|---|
| Size and price | ||
| Market cap | $1.3B | $747M |
| Share price | $38.26 | $21.20 |
| Change, 1 year | 14.9% | 11.3% |
| Change, 5 years | 162% | −12.4% |
| Beta (5Y) | 0.50 | 0.38 |
| Employees | 132 | – |
| StockData Score | ||
| Total score | 12 | 13 (better) |
| Valuation score | 4 (better) | 3 |
| Growth score | 2 | 3 (better) |
| Performance score | 0 | 1 (better) |
| Health score | 6 (better) | 3 |
| Dividend score | 0 | 3 (better) |
| Valuation | ||
| P/E | 10.5× | – |
| P/S | 1.9× | 0.6× (better) |
| P/B | 1.9× | – |
| EV/EBITDA | – | 1.4× |
| P/FCF | 18.5× | 1.7× (better) |
| PEG | 0.22 | – |
| FCF yield | 5.4% | 59.4% (better) |
| Fair value | $61.39 | $144.11 |
| Margin of safety | 37.7% | 85.3% (better) |
| Growth | ||
| Revenue growth (TTM) | 1.3% | 9.4% (better) |
| Revenue growth, 5Y average | 11.8% (better) | 3.8% |
| Net income growth (TTM) | – | 20.4% |
| EPS growth (TTM) | 145% | – |
| EPS growth, 5Y average | 98.2% | – |
| Profitability | ||
| Gross margin | 27.2% | 31.4% (better) |
| Operating margin | – | 29.0% |
| Net margin | – | 4.8% |
| FCF margin | 10.4% | 35.8% (better) |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Interest coverage | – | 17.3× |
| Current ratio | 6.88 (better) | 3.52 |
| Altman Z-score | 11.38 (better) | 3.09 |
| Piotroski F-score | – | 5 |
| Dividends and buybacks | ||
| Dividend yield | – | 6.7% |
| Buyback yield | 0.12% | – |
| Shareholder yield | 0.12% | 6.7% (better) |
| Ownership | ||
| Held by institutions | 80.3% | 29.1% |
| Held by insiders | 13.1% | 44.3% |
| Insider net buying, 12 months | −$7.1M | – |
| Short interest, % of float | 2.4% | 0.75% |
Go deeper
- REX stock overview
- REX income statement
- REX valuation and score
- WLKP stock overview
- WLKP income statement
- WLKP valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.